Summary
Overview
Work History
Education
Certification
Honors and Awards
Affiliations
Research
Publications
Speaking Engagements
Timeline
Generic

Daniel Efiom-Ekaha MD, FACP.

York,PA

Summary

Dedicated clinician, experienced leader with strong background in guiding teams, managing complex projects, and achieving strategic objectives. Excels in developing efficient processes, ensuring high standards, and aligning efforts with organizational goals. Known for collaborative approach and commitment to excellence.

Overview

24
24
years of professional experience
1
1
Certification

Work History

President

Cancer Care Associates of York
11.2006 - Current
  • Built a diverse workforce through targeted recruiting efforts focused on diversity, equity, and inclusion principles.
  • Hired and managed employees to maximize productivity while training staff on best practices and protocols.
  • Navigated complex regulatory environments while maintaining compliance across all aspects of the organization''s operations.
  • Managed crisis situations effectively while minimizing disruption to daily operations.
  • Analyzed industry trends and tracked competitor activities to inform decision making.
  • Managed financial, operational and human resources to optimize business performance.
  • Devised and presented business plans and forecasts to board of directors.

Attending Physician, Hematology & Medical Oncology

Wellspan Health- York Hospital
11.2006 - Current
  • Led interdisciplinary team meetings to discuss complex cases, fostering collaboration among healthcare professionals for improved patient outcomes.
  • Optimized patient care by collaborating with multidisciplinary teams, including nurses, therapists, and social workers.
  • Implemented individualized care plans to improve patient outcomes.
  • Participated in quality improvement initiatives to optimize clinical processes and enhance overall patient care standards.
  • Enhanced collaboration among healthcare team members for optimal patient care delivery.
  • Contributed to ongoing professional development by actively participating in continuing education courses, workshops, and seminars related to clinical practice advancements.
  • Mentored junior physicians and medical students, fostering professional growth and skill development within the healthcare team.
  • Educated medical professionals on effective strategies for managing acute and long-term requirements of different patients.
  • Negotiated with insurance companies to secure coverage for new, effective treatments not previously included in plans.

Attending Physician, Hematology & Medical Oncology

University of Pittsburgh Medical Center (UPMC)
11.2006 - Current
  • Contributed to ongoing professional development by actively participating in continuing education courses, workshops, and seminars related to clinical practice advancements.
  • Mentored junior physicians and medical students, fostering professional growth and skill development within the healthcare team.

Prseident

Community Hematology Oncology Consortium (CHOC)
11.2022 - Current
  • Navigated complex regulatory environments while maintaining compliance across all aspects of the organization''s operations.
  • Formulated and executed strategic initiatives to improve product offerings.
  • Analyzed industry trends and tracked competitor activities to inform decision making.
  • Monitored key business risks and established risk management procedures.
  • Cultivated strong relationships with external partners to foster collaboration and maximize resources.
  • Maintained P&L and shouldered corporate fiscal responsibility.

Vice President

ONCare Alliance Network
03.2024 - Current
  • Demonstrated proficient leadership skills to motivate employees and build competent teams.
  • Collaborated with senior management to develop strategic initiatives and long term goals.
  • Represented organization at industry conferences and events.

Board Member

Apple Hill Medical Center Management Board
01.2018 - Current
  • Served as advocate and ambassador for organization by fully engaging, identifying, and securing resources and partnerships to advance mission.
  • Reviewed financial reports, budgets, and audit results to monitor the organization''s fiscal health.
  • Provided guidance and leadership on strategic planning initiatives and organizational development.
  • Served as a strong advocate for corporate social responsibility, influencing positive community impact.

Board Member

First Residential Pierhomes Association Board
01.2021 - 12.2023
  • Reviewed financial reports, budgets, and audit results to monitor the organization''s fiscal health.
  • Served as a strong advocate for corporate social responsibility, influencing positive community impact.

Clinical Instructor, Hematology/ Oncology

State University of New York
07.2023 - 06.2026
  • Participated in faculty meetings, committees, and continuing education events to stay current on nursing education trends and best practices.
  • Provided educational lectures and facilitated discussions on weekly basis.
  • Collaborated with fellow instructors to ensure consistency in teaching methods and curriculum content.

Chief Resident, Internal Medicine

Brooklyn Hospital Center
07.2002 - 06.2003
  • Utilized strong organizational skills to balance competing priorities successfully during periods of high workload intensity or limited personnel availability.
  • Conducted comprehensive case presentations at weekly conferences, engaging colleagues in meaningful discussions surrounding diagnostic dilemmas or challenging management decisions.
  • Coordinated and integrated health care resources for community-based programs.
  • Improved patient outcomes and delivery of care through improved clinical quality processes.

Education

Fellowship, Hematology & Medical Oncology -

State University of New York
Brooklyn, NY
07.2006

Internal Medicine Residency -

Brooklyn Hospital Center
Brooklyn, NY
06.2003

Royal College of Obstetrics And Gynecology (MRCOG) - Residency, Obstetrics And Gynecology

Cornwall Regional Hospital
Jamaica
12.1999

Medical Bachelor And Bachelor of Surgery - Medicine And Surgery

University College Hospital, University of Ibadan
Nigeria
09.1995

Certification

  • Diplomate, American Board of Internal Medicine. Board Certification in Internal Medicine.


  • Diplomate, American Board of Internal Medicine. Board Certification in Hematology.


  • Diplomate, American Board of Internal Medicine. Board Certification in Medical Oncology


  • Diplomate American Board of Hospice and Palliative Medicine. Board Certified in Hospice and Palliative Medicine


  • Royal College of Obstetricians and Gynecologists, London, UK. M.R.C.O.G. Part 1. 1999

Honors and Awards

  • Targeted Oncology, Oncology Icons Award. 2023


  • Resident of The Year, The Brooklyn Hospital Center. Brooklyn NY. 2001


  • Intern of The Month, The Brooklyn Hospital Center. Brooklyn NY. 2000


  • Nigerian Medical Association, Commendation for Original Research. 1995

Affiliations

  • American Society of Clinical Oncology
  • Fellow, American College of Physicians
  • American Society of Hematology
  • American Medical Association
  • American Board of Internal Medicine

Research

Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)


Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer


Global Phase III Study to Assess the Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9)


Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I)


Harbinger Health Collection of Blood and Tissue Samples from Cancer and NonCancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test


Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors


DNA evaluation of fragments for early interception - Lung Cancer  Training Study (DELFI-L101 Study)


Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello-292)


An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects with Solid Tumors or Lymphoma


A Phase 3 OpenLabel, Randomized Study of Pirtobrutinib (LOXO-305) versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)


Tempus SCLC Observational Study: A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients with Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing Assays


Tempus GEMINI NSCLC Study: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Non-Small Cell Lung Cancer (NSCLC)


A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)


A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor A ctDNA Guided Early Switch Study


A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease


A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy


A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy

Publications

Daniel Efiom-Ekaha, A.G. Patel. Primary Peritoneal Cancer. Online book chapter eMedicine Journal, February 28 2003, VOLUME 4, Number 2


Daniel Efiom-Ekaha, A.G. Patel Hematopoietic stem Cell Transplantation. eMedicine Journal, October 13 2004, VOLUME 5, Number 10

A. S. Braverman, B. S. Kamenova, D. Efiom-Ekaha, C. Sohn; Brachial Plexus Syndrome in Breast Cancer Patients: A Complication of Locally Advanced or Recurrent Tumor. Proc Annu Meet Am soc Clin Oncol 2005; 23; 748.


Daniel Efiom-Ekaha, Joseph Feldman, Susan Gottesman, Natalya Krichmar, Olugbenga Olowokure, Jasotha Sanmugaharajah, Iuliana Shapira, William B Solomon, Emily Qian Chen. Infusional adriamycin based chemotherapy significantly improves the survival of Human T-cell Lymphotropic Virus-I Induced Acute Type Adult T-cell Leukemia Lymphoma. Accepted for Poster Presentation at the 2005 Annu Meet Am Soc Hem (abstract # 1484).


Boriana Kamenova · Albert S. Braverman. Michael Schwartz · Chul Sohn · Christopher Lange Daniel Efiom-Ekaha · Marvin Rotman · Harold Yoon Effective treatment of the brachial plexus syndrome in breast cancer patients by early detection and control of loco-regional metastases with radiation or systemic therapy. International Journal of Clinical Oncology Volume 14, Number 3  219-224


Daniel Efiom-Ekaha, M.D. Kelly Khai Li Yap, M.D.; Modified Bloom Richardson Score as a reliable predictor of breast cancer recurrence. Abstract presentation, 2011 Breast Cancer Symposium, San Francisco, Ca.


Daniel Efiom-Ekaha, M.D Kelly Khai Li Yap, M.D.; Obesity is not associated with increased recurrence risk in ER-positive breast cancer Abstract presentation, 2011 Breast Cancer Symposium, San Francisco, Ca.


Daniel Efiom-Ekaha, M.D Kelly Khai Li Yap, M.D.; Do younger women with early breast cancer have a higher recurrence risk? Abstract presentation, 2011 Breast Cancer Symposium, San Francisco, Ca


Daniel Efiom-Ekaha, M.D, Kelly Khai Li Yap, M.D.; Joseph Kannarkatt MD, McCormick, Timothy C MD. Ovarian and Thyroid Metastases from Renal Clear Cell Carcinoma (RCC) Successfully Treated with Metastectomy. Abstract presentation 2012 International Kidney Cancer Symposium.


L.M. de Souza-Lawrence, A.B. Shah, M. Young, F. Asrari, D.A. Frassica, V. Stearns, J. Werner, D.M. Efiom-Ekaha, A.C. Wolff, R.C. Zellars

Phase I/II Trial of Partial Breast Irradiation (PBI) With Various Concurrent Chemotherapy Regimens: Assessment of Skin Toxicity, Cosmetic Outcomes, and Disease Recurrence. International Journal of Radiation Oncology • Biology • Physics Volume 84, Issue 3, Supplement, Pages S219–S220, November 1, 2012

Speaking Engagements

Taiho Oncology Speaker Bureau-LONSURF® + bevacizumab for the Treatment of 3L Metastatic Colorectal Cancer.


BeiGene Speaker Bureau- Discussion of Brukinsa for adult patients with CLL/SLL + 215


Boehringer Ingelheim Speaker Bureau- Gilotrif in NSCLCa


Dendreon Speaker Bureau- Adoption of Sipuleucel-T (Provenge) in Prostate Cancer.


Celgene Speaker Bureau- NabPaclitaxel in Pancreatic Cancer


Genomic Health Speaker-  Advanced Oncotype Dx in Breast Cancer


Norvatis Speaker Bureau- Everolimus in Multiple Malignancies. Oral iron Chelation with Exjade.


Lilly Oncology Speaker Bureau-Thoracic Oncology 


Millenium EPIC Speaker Bureau- Proteasome Inhibition in Cancer

Timeline

Vice President

ONCare Alliance Network
03.2024 - Current

Clinical Instructor, Hematology/ Oncology

State University of New York
07.2023 - 06.2026

Prseident

Community Hematology Oncology Consortium (CHOC)
11.2022 - Current

Board Member

First Residential Pierhomes Association Board
01.2021 - 12.2023

Board Member

Apple Hill Medical Center Management Board
01.2018 - Current

President

Cancer Care Associates of York
11.2006 - Current

Attending Physician, Hematology & Medical Oncology

Wellspan Health- York Hospital
11.2006 - Current

Attending Physician, Hematology & Medical Oncology

University of Pittsburgh Medical Center (UPMC)
11.2006 - Current

Chief Resident, Internal Medicine

Brooklyn Hospital Center
07.2002 - 06.2003
  • Diplomate, American Board of Internal Medicine. Board Certification in Internal Medicine.


  • Diplomate, American Board of Internal Medicine. Board Certification in Hematology.


  • Diplomate, American Board of Internal Medicine. Board Certification in Medical Oncology


  • Diplomate American Board of Hospice and Palliative Medicine. Board Certified in Hospice and Palliative Medicine


  • Royal College of Obstetricians and Gynecologists, London, UK. M.R.C.O.G. Part 1. 1999

Fellowship, Hematology & Medical Oncology -

State University of New York

Internal Medicine Residency -

Brooklyn Hospital Center

Royal College of Obstetrics And Gynecology (MRCOG) - Residency, Obstetrics And Gynecology

Cornwall Regional Hospital

Medical Bachelor And Bachelor of Surgery - Medicine And Surgery

University College Hospital, University of Ibadan
Daniel Efiom-Ekaha MD, FACP.